Market Exclusivity Decision Pending For Bayer’s First-In-Class OTC Switch Astepro Allergy

 
• By Malcolm Spicer

Astepro Allergy’s attributes include being the first steroid-free, antihistamine nasal spray for allergies available OTC in the US and the first indicated for indoor and outdoor allergy relief. An attribute yet to be determined will have most influence on revenue boost for Bayer: three-year market exclusivity.

Astepro Allergy labeling was approved with Bayer's NDA for an OTC switch of azelastine hydrochloride nasal spray. • Source: FDA

More from Regulation

More from Policy & Regulation